WCA Recommendations for the Long-Term Treatment of Social Phobia

Michael Van Ameringen, Christer Allgulander, Borwin Bandelow, John H. Greist, Eric Hollander, Stuart A. Montgomery, David J. Nutt, Ahmed Okasha, Mark H. Pollack, Dan J. Stein, Richard P. Swinson

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

What is the best approach for treating patients with social phobia (social anxiety disorder) over the long term? Social phobia is the most common anxiety disorder, with reported prevalence rates of up to 18.7%. Social phobia is characterized by a marked and persistent fear of being observed or evaluated by others in social performance or interaction situations and is associated with physical, cognitive, and behavioral (ie, avoidance) symptoms. The onset of social phobia typically occurs in childhood or adolescence and the clinical course, if left untreated, is usually chronic, unremitting, and associated with significant functional impairment. Social phobia exhibits a high degree of comorbidity with other psychiatric disorders, including mood disorders, anxiety disorders, and substance abuse/dependence. Few people with social phobia seek professional help despite the existence of beneficial treatment approaches. The efficacy, tolerability, and safety of the selective serotonin reuptake inhibitors (SSRIs), evidenced in randomized clinical trials, support these agents as first-line treatment. The benzodiazepine clonazepam and certain monoamine oxidase inhibitors (representing both reversible and nonreversible inhibitors) may also be of benefit. Treatment of social phobia may need to be continued for several months to consolidate response and achieve full remission. The SSRIs have shown benefit in long-term treatment trials, while long-term treatment data from clinical studies of clonazepam are limited but support the drug's efficacy. There is also evidence for the effectiveness of exposure-based strategies of cognitive-behavioral therapy, and controlled studies suggest that the effects of treatment are generally maintained at long-term follow-up. In light of the chronicity and disability associated with social phobia, as well as the high relapse rate after short-term therapy, it is recommended that effective treatment be continued for at least 12 months.

Original languageEnglish (US)
Pages (from-to)40-52
Number of pages13
JournalCNS Spectrums
Volume8
Issue number8 SUPPL. 1
StatePublished - Aug 2003
Externally publishedYes

Fingerprint

Clonazepam
Therapeutics
Serotonin Uptake Inhibitors
Anxiety Disorders
Substance-Related Disorders
Social Phobia
Monoamine Oxidase Inhibitors
Cognitive Therapy
Mood Disorders
Benzodiazepines
Fear
Psychiatry
Comorbidity
Randomized Controlled Trials
Safety
Recurrence
Pharmaceutical Preparations
Clinical Studies

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology

Cite this

Van Ameringen, M., Allgulander, C., Bandelow, B., Greist, J. H., Hollander, E., Montgomery, S. A., ... Swinson, R. P. (2003). WCA Recommendations for the Long-Term Treatment of Social Phobia. CNS Spectrums, 8(8 SUPPL. 1), 40-52.

WCA Recommendations for the Long-Term Treatment of Social Phobia. / Van Ameringen, Michael; Allgulander, Christer; Bandelow, Borwin; Greist, John H.; Hollander, Eric; Montgomery, Stuart A.; Nutt, David J.; Okasha, Ahmed; Pollack, Mark H.; Stein, Dan J.; Swinson, Richard P.

In: CNS Spectrums, Vol. 8, No. 8 SUPPL. 1, 08.2003, p. 40-52.

Research output: Contribution to journalArticle

Van Ameringen, M, Allgulander, C, Bandelow, B, Greist, JH, Hollander, E, Montgomery, SA, Nutt, DJ, Okasha, A, Pollack, MH, Stein, DJ & Swinson, RP 2003, 'WCA Recommendations for the Long-Term Treatment of Social Phobia', CNS Spectrums, vol. 8, no. 8 SUPPL. 1, pp. 40-52.
Van Ameringen M, Allgulander C, Bandelow B, Greist JH, Hollander E, Montgomery SA et al. WCA Recommendations for the Long-Term Treatment of Social Phobia. CNS Spectrums. 2003 Aug;8(8 SUPPL. 1):40-52.
Van Ameringen, Michael ; Allgulander, Christer ; Bandelow, Borwin ; Greist, John H. ; Hollander, Eric ; Montgomery, Stuart A. ; Nutt, David J. ; Okasha, Ahmed ; Pollack, Mark H. ; Stein, Dan J. ; Swinson, Richard P. / WCA Recommendations for the Long-Term Treatment of Social Phobia. In: CNS Spectrums. 2003 ; Vol. 8, No. 8 SUPPL. 1. pp. 40-52.
@article{ce15a50eb52941f094c984af51a461e6,
title = "WCA Recommendations for the Long-Term Treatment of Social Phobia",
abstract = "What is the best approach for treating patients with social phobia (social anxiety disorder) over the long term? Social phobia is the most common anxiety disorder, with reported prevalence rates of up to 18.7{\%}. Social phobia is characterized by a marked and persistent fear of being observed or evaluated by others in social performance or interaction situations and is associated with physical, cognitive, and behavioral (ie, avoidance) symptoms. The onset of social phobia typically occurs in childhood or adolescence and the clinical course, if left untreated, is usually chronic, unremitting, and associated with significant functional impairment. Social phobia exhibits a high degree of comorbidity with other psychiatric disorders, including mood disorders, anxiety disorders, and substance abuse/dependence. Few people with social phobia seek professional help despite the existence of beneficial treatment approaches. The efficacy, tolerability, and safety of the selective serotonin reuptake inhibitors (SSRIs), evidenced in randomized clinical trials, support these agents as first-line treatment. The benzodiazepine clonazepam and certain monoamine oxidase inhibitors (representing both reversible and nonreversible inhibitors) may also be of benefit. Treatment of social phobia may need to be continued for several months to consolidate response and achieve full remission. The SSRIs have shown benefit in long-term treatment trials, while long-term treatment data from clinical studies of clonazepam are limited but support the drug's efficacy. There is also evidence for the effectiveness of exposure-based strategies of cognitive-behavioral therapy, and controlled studies suggest that the effects of treatment are generally maintained at long-term follow-up. In light of the chronicity and disability associated with social phobia, as well as the high relapse rate after short-term therapy, it is recommended that effective treatment be continued for at least 12 months.",
author = "{Van Ameringen}, Michael and Christer Allgulander and Borwin Bandelow and Greist, {John H.} and Eric Hollander and Montgomery, {Stuart A.} and Nutt, {David J.} and Ahmed Okasha and Pollack, {Mark H.} and Stein, {Dan J.} and Swinson, {Richard P.}",
year = "2003",
month = "8",
language = "English (US)",
volume = "8",
pages = "40--52",
journal = "CNS Spectrums",
issn = "1092-8529",
publisher = "MBL Communications",
number = "8 SUPPL. 1",

}

TY - JOUR

T1 - WCA Recommendations for the Long-Term Treatment of Social Phobia

AU - Van Ameringen, Michael

AU - Allgulander, Christer

AU - Bandelow, Borwin

AU - Greist, John H.

AU - Hollander, Eric

AU - Montgomery, Stuart A.

AU - Nutt, David J.

AU - Okasha, Ahmed

AU - Pollack, Mark H.

AU - Stein, Dan J.

AU - Swinson, Richard P.

PY - 2003/8

Y1 - 2003/8

N2 - What is the best approach for treating patients with social phobia (social anxiety disorder) over the long term? Social phobia is the most common anxiety disorder, with reported prevalence rates of up to 18.7%. Social phobia is characterized by a marked and persistent fear of being observed or evaluated by others in social performance or interaction situations and is associated with physical, cognitive, and behavioral (ie, avoidance) symptoms. The onset of social phobia typically occurs in childhood or adolescence and the clinical course, if left untreated, is usually chronic, unremitting, and associated with significant functional impairment. Social phobia exhibits a high degree of comorbidity with other psychiatric disorders, including mood disorders, anxiety disorders, and substance abuse/dependence. Few people with social phobia seek professional help despite the existence of beneficial treatment approaches. The efficacy, tolerability, and safety of the selective serotonin reuptake inhibitors (SSRIs), evidenced in randomized clinical trials, support these agents as first-line treatment. The benzodiazepine clonazepam and certain monoamine oxidase inhibitors (representing both reversible and nonreversible inhibitors) may also be of benefit. Treatment of social phobia may need to be continued for several months to consolidate response and achieve full remission. The SSRIs have shown benefit in long-term treatment trials, while long-term treatment data from clinical studies of clonazepam are limited but support the drug's efficacy. There is also evidence for the effectiveness of exposure-based strategies of cognitive-behavioral therapy, and controlled studies suggest that the effects of treatment are generally maintained at long-term follow-up. In light of the chronicity and disability associated with social phobia, as well as the high relapse rate after short-term therapy, it is recommended that effective treatment be continued for at least 12 months.

AB - What is the best approach for treating patients with social phobia (social anxiety disorder) over the long term? Social phobia is the most common anxiety disorder, with reported prevalence rates of up to 18.7%. Social phobia is characterized by a marked and persistent fear of being observed or evaluated by others in social performance or interaction situations and is associated with physical, cognitive, and behavioral (ie, avoidance) symptoms. The onset of social phobia typically occurs in childhood or adolescence and the clinical course, if left untreated, is usually chronic, unremitting, and associated with significant functional impairment. Social phobia exhibits a high degree of comorbidity with other psychiatric disorders, including mood disorders, anxiety disorders, and substance abuse/dependence. Few people with social phobia seek professional help despite the existence of beneficial treatment approaches. The efficacy, tolerability, and safety of the selective serotonin reuptake inhibitors (SSRIs), evidenced in randomized clinical trials, support these agents as first-line treatment. The benzodiazepine clonazepam and certain monoamine oxidase inhibitors (representing both reversible and nonreversible inhibitors) may also be of benefit. Treatment of social phobia may need to be continued for several months to consolidate response and achieve full remission. The SSRIs have shown benefit in long-term treatment trials, while long-term treatment data from clinical studies of clonazepam are limited but support the drug's efficacy. There is also evidence for the effectiveness of exposure-based strategies of cognitive-behavioral therapy, and controlled studies suggest that the effects of treatment are generally maintained at long-term follow-up. In light of the chronicity and disability associated with social phobia, as well as the high relapse rate after short-term therapy, it is recommended that effective treatment be continued for at least 12 months.

UR - http://www.scopus.com/inward/record.url?scp=1542349819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542349819&partnerID=8YFLogxK

M3 - Article

C2 - 14767397

AN - SCOPUS:1542349819

VL - 8

SP - 40

EP - 52

JO - CNS Spectrums

JF - CNS Spectrums

SN - 1092-8529

IS - 8 SUPPL. 1

ER -